Arno Therapeutics Reports Fourth Quarter 2014 Financial and Business Update – Nasdaq

Nasdaq
For the three months ended December 31, 2014, Arno reported net income of $4.6 million, or $0.22 per share, which includes non-cash income of $8.4 million related to the decrease in derivative liability of common stock warrants, and $1.0 million of non

and more

…read more

Scroll to Top